Search Videos by Topic or Participant
Browse by Series:

Potential New Biomarkers in Lung Cancer

Panelists: D. Ross Camidge, MD, PhD, University of Colorado;Ramaswamy Govindan, MD, Siteman; Roy S. Herbst, MD, PhD, Yale; Corey J. Langer, MD, Penn
Published: Wednesday, Dec 03, 2014
For High-Definition, Click
Earlier studies have suggested that patients with rich expression of EGFR might benefit from treatment with an EGFR-targeted monoclonal antibody, such as necitumumab. Researchers are currently exploring EGFR expression in tissues samples from patients enrolled in the phase III SQUIRE trial, which examined necitumumab in non-small cell lung cancer (NSCLC).

Additionally, there is interest in CDKN2A deletions as a potential predictor of response to CDK4/6 inhibitors. In a phase II study, treatment with palbociclib was well tolerated and demonstrated stable disease in 50% of evaluable patients in previously treated patients with CDKN2A inactivated NSCLC. These results warrant further investigation, believes Ramaswamy Govindan, MD.
Slider Left
Slider Right
For High-Definition, Click
Earlier studies have suggested that patients with rich expression of EGFR might benefit from treatment with an EGFR-targeted monoclonal antibody, such as necitumumab. Researchers are currently exploring EGFR expression in tissues samples from patients enrolled in the phase III SQUIRE trial, which examined necitumumab in non-small cell lung cancer (NSCLC).

Additionally, there is interest in CDKN2A deletions as a potential predictor of response to CDK4/6 inhibitors. In a phase II study, treatment with palbociclib was well tolerated and demonstrated stable disease in 50% of evaluable patients in previously treated patients with CDKN2A inactivated NSCLC. These results warrant further investigation, believes Ramaswamy Govindan, MD.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x